Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry

BACKGROUND: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inh...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A., Miletello, G. P., Curti, B., Agarwal, Neeraj, Hauke, R., Mahoney, K. M., Moon, H., Treisman, J., Tykodi, S. S., Daniels, G., Morse, M. A., Wong, M. K. K., Kaufman, H., Gregory, N., McDermott, D. F.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437874/
https://ncbi.nlm.nih.gov/pubmed/30917871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0567-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars